Skip to main content
TipRanks
Go Ultimate75% OFF

Royalty Pharma (RPD) Stock Price & Analysis

6 Followers

RPD Stock Chart & Stats

€62.66€0.34(0.55%)
At close: 5:30 PM GMT+1
€50€55€60Aug 24Sep 8Sep 21Oct 5Oct 21Nov 2Nov 16
Day’s Range
EUR 62.66 - EUR 63.11
52-Week Range
EUR 31.65 - EUR 63.80
Previous Close
EUR 62.32
Volume
N/A
Average Volume (3M)
21
Market Cap
EUR 35.76B
Enterprise Value
EUR 43.51B
Total Cash (Recent Filing)
EUR 544.86M
Total Debt (Recent Filing)
EUR 8.59B
Price to Earnings (P/E)
41.0
Beta
0.32
Next Earnings
Feb 16, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
1.35%

Bulls Say, Bears Say

Bulls Say

Recurring Receipt Growth

Rising recurring royalty receipts and repeated guidance increases indicate durable demand across the underlying portfolio. This supports visibility into cash generation, strengthens funding capacity for new royalty acquisitions, and suggests growth is not dependent solely on occasional milestone payments.

High-margin Cash Generation

The royalty model converts a large share of receipts into portfolio cash flow because Royalty Pharma generally avoids direct drug development, manufacturing, and commercialization costs. High conversion can support acquisitions, debt service, and shareholder returns over the next several quarters.

Pipeline And Portfolio Diversification

A broad portfolio spanning multiple products and development programs can reduce reliance on any single medicine while creating avenues for future royalty growth. Successful approvals and pivotal trials expand the potential cash-flow base and reinforce the company’s sourcing advantage.

Bears Say

Meaningful Leverage

Debt provides acquisition capacity but creates a continuing claim on royalty cash flows through interest expense and principal obligations. Leverage can reduce flexibility if product receipts weaken or acquisition opportunities require additional funding, even with long debt duration and an undrawn revolver.

Maturing Product Headwinds

Declines from established products show that portfolio diversification does not eliminate erosion from aging or weakening assets. Continued pressure on major royalties could temper medium-term receipt growth and require successful replacement from newer products and development-stage investments.

Lower Contractual Receipts

Lower milestone and contractual receipts reduce a non-recurring contributor to total cash inflows and make results more dependent on underlying royalty collections. This may increase variability in reported revenue and limit the benefit of development events during the forecast period.

Royalty Pharma News

RPD FAQ

What was Royalty Pharma’s price range in the past 12 months?
Royalty Pharma lowest stock price was €31.65 and its highest was €63.80 in the past 12 months.
What is Royalty Pharma’s market cap?
Royalty Pharma’s market cap is €35.76B.
When is Royalty Pharma’s upcoming earnings report date?
Royalty Pharma’s next earnings report is estimated for Feb 16, 2027 (not yet confirmed), which is in 91 days.
How were Royalty Pharma’s earnings last quarter?
Royalty Pharma released its earnings results on Nov 04, 2026. The company reported €1.082 earnings per share for the quarter, beating the consensus estimate of €1.057 by €0.024.
Is Royalty Pharma overvalued?
According to Wall Street analysts Royalty Pharma’s price is currently Undervalued.
Does Royalty Pharma pay dividends?
Royalty Pharma does not currently pay dividends.
What is Royalty Pharma’s EPS estimate?
Royalty Pharma’s EPS estimate is 1.40.
How many shares outstanding does Royalty Pharma have?
Royalty Pharma has 445,265,800 shares outstanding.
What happened to Royalty Pharma’s price movement after its last earnings report?
Royalty Pharma reported an EPS of €1.082 in its last earnings report, beating expectations of €1.057. Following the earnings report the stock price went down -1.868%.
Which hedge fund is a major shareholder of Royalty Pharma?
Hedge funds hold Royalty Pharma shares: the largest hedge-fund position in Royalty Pharma is 1,700,912,598 shares, and hedge funds decreased their holdings by 249.9K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology